Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 2, 2011, Pages

  Antonelli, Alessandro ^a   Bocci, Guido ^a   La Motta, Concettina ^a   Ferrari, Silvia Martina ^a   Fallahi, Poupak ^a   Fioravanti, Anna ^a   Sartini, Stefania ^a   Minuto, Michele ^a   Piaggi, Simona ^a   Corti, Alessandro ^a   Alì, Greta ^a   Berti, Piero ^a   Fontanini, Gabriella ^a   Danesi, Romano ^a   Da Settimo, Federico ^a   Miccoli, Paolo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLM 29; CLM 3; PYRAZOLOPYRIMIDINE DERIVATIVE; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RECURRENCE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THERAPY EFFECT; THYROID CANCER; TUMOR VOLUME; XENOTRANSPLANTATION;

ANIMALS; ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; CAPILLARIES; CARCINOMA, PAPILLARY; CELL COUNT; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DNA, NEOPLASM; HUMANS; MALE; MICE; MICE, NUDE; MICRODISSECTION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PYRAZOLES; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBOSPONDINS; THYROID NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MUS;

EID: 79951709994     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-1905     Document Type: Article

References (42)

1. Mazzaferri EL, Massoll N 2002 Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocr Relat Cancer 9:227-247 (Pubitemid 36240764)
2. Schlumberger MJ 1998 Papillary and follicular thyroid carcinoma. N Engl J Med 338:297-306 (Pubitemid 28065257)
3. Haugen BR 1999 Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 16:34-41
4. Fagin JA 2004 How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol 183:249-256 (Pubitemid 39562707)
5. Krause DS, VanEtten RA 2005 Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172-187 (Pubitemid 41058349)
6. Antonelli A, Fallahi P, Ferrari SM, Carpi A, Berti P, Materazzi G, Minuto M, Guastalli M, Miccoli P 2008 Dedifferentiated thyroid cancer: a therapeutic challenge. Biomed Pharmacother 62:559-563
7. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M 2002 ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62:7284-7290 (Pubitemid 36025251)
8. Lanzi C, Cassinelli G, Cuccuru G, Zaffaroni N, Supino R, Vignati S, Zanchi C, Yamamoto M, Zunino F 2003 Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1. Cell Mol Life Sci 60:1449-1459 (Pubitemid 36900526)
9. Mologni L, Sala E, Cazzaniga S, Rostagno R, Kuoni T, Puttini M, Bain J, Cleris L, Redaelli S, Riva B, Formelli F, Scapozza L, Gambacorti-Passerini C 2006 Inhibition of RET tyrosine kinase by SU5416. J Mol Endocrinol 37:199-212 (Pubitemid 44615293)
10. Carlomagno F, Vitagliano D, Guida T, Napolitano M, Vecchio G, Fusco A, Gazit A, Levitzki A, Santoro M 2002 The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res 62:1077-1082 (Pubitemid 34160290)
11. Carlomagno F, Vitagliano D, Guida T, Basolo F, Castellone MD, Melillo RM, Fusco A, Santoro M 2003 Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d] pyrimidine (PP2). J Clin Endocrinol Metab 88:1897-1902 (Pubitemid 36623420)
12. Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, Park SH, Hwang JH, Rha SY, Kweon GR, Lee SJ, Jo KW, Shong M 2006 An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91:4070-4076 (Pubitemid 44536887)
13. Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L, Bready J, Estrada J, Cattley R, Kaufman S, Chen D, Gan Y, Kumar G, Meyer J, Neervannan S, Alva G, Talvenheimo J, Montestruque S, Tasker A, Patel V, Radinsky R, Kendall R 2006 AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 66:8715-8721 (Pubitemid 44449188)
14. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M 2006 BAY43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98:326-334 (Pubitemid 43338212)
15. Vidal M, Wells S, Ryan A, Cagan R 2005 ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Res 65:3538-3541 (Pubitemid 40616327)
16. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB 2008 Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26:4708-4713
17. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS 2008 Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719
18. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ; Motesanib Thyroid Cancer Study Group 2008 Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359:31-42
19. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely Jr PE, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH 2009 Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684
20. Antonelli A, Ferri C, Ferrari SM, Sebastiani M, Colaci M, Ruffilli I, Fallahi P 2010 New targeted molecular therapies for dedifferentiated thyroid cancer. J Oncol 2010:921682
21. Klebl BM, Müller G 2005 Second generation kinase inhibitors. Expert Opin Ther Targets 9:975-993
22. Casanovas O, Hicklin DJ, Bergers G, Hanahan D 2005 Drug resistance by evasion of antiangiogenic targeting of VEGF signalling in late-stage pancreatic islet tumors. Cancer Cell 8:299-309 (Pubitemid 41443415)
23. Taliani S, La Motta C, Mugnaini L, Simorini F, Salerno S, Marini AM, Da Settimo F, Cosconati S, Cosimelli B, Greco G, Limongelli V, Marinelli L, Novellino E, Ciampi O, Daniele S, Trincavelli ML, Martini C 2010 Novel N2-substituted pyrazolo[3,4-d]pyrimidine adenosine A3 receptor antagonists: inhibition of A3-mediated human glioblastoma cell proliferation. J Med Chem 53:3954-3963
24. Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Piaggi S, Gelmini S, Lupi C, Minuto M, Berti P, Benvenga S, Basolo F, Orlando C, Miccoli P 2009 Dysregulation of secretion of CXC α-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-γ agonists. Endocr Relat Cancer 16:1299-1311
25. Zhu Z, Ciampi R, Nikiforova MN, Gandhi M, Nikiforov YE 2006 Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab 91:3603-3610 (Pubitemid 44402144)
26. Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Franceschini SS, Serio M, Ferrannini E 2006 Interferon-γ -inducible α-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-γ agonists. J Clin Endocrinol Metab 91:614-620 (Pubitemid 43236933)
27. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, Marchetti I, Ugolini C, Basolo F, Miccoli P, Ferrannini E 2008 Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. Eur J Endocrinol 159:283-291
28. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, Minuto M, Giannini R, Marchetti I, Barani L, Basolo F, Ferrannini E, Miccoli P 2009 Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells. Clin Endocrinol (Oxf) 70:946-953
29. Bocci G, Francia G, Man S, Lawler J, Kerbel RS 2003 Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 100:12917-12922 (Pubitemid 37340000)
30. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, Pollok BA, Connelly PA 1996 Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem 271:695-701
31. Ye L, Santarpia L, Gagel RF 2010 The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors. Endocr Rev 31:578-599
32. Blumenthal RD, Goldenberg DM 2007 Methods and goals for the use of in vitro and in vivo chemosensitivity testing. Mol Biotechnol 35:185-197
33. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, Barani L, Marchetti I, Ferrannini E, Miccoli P 2008 Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests. Clin Endocrinol 69:148-152 (Pubitemid 351847276)
34. Lin JD, Chao TC, Weng HF, Huang HS, Ho YS 1996 Establishment of xenografts and cell lines from well-differentiated human thyroid carcinoma. J Surg Oncol 63:112-118
35. Mirochnik Y, Kwiatek A, Volpert OV 2008 Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments. Curr Drug Targets 9:851-862
36. Tan K, Lawler J 2009 The interaction of Thrombospondins with extracellular matrix proteins. J Cell Commun Signal 3:177-187
37. Zhang X, Kazerounian S, Duquette M, Perruzzi C, Nagy JA, Dvorak HF, Parangi S, Lawler J 2009 Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J 23:3368-3376
38. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK 2002 Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416:279-280 (Pubitemid 34260234)
39. Sawyers CL 2002 Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. Cancer Cell 1:13-15 (Pubitemid 41039170)
40. Morisi R, Celano M, Tosi E, Schenone S, Navarra M, Ferretti E, Costante G, Durante C, Botta G, D'Agostino M, Brullo C, Filetti S, Botta M, Russo D 2007 Growth inhibition of medullary thyroid carcinoma cells by pyrazolo-pyrimidine derivatives. J Endocrinol Invest 30:RC31-RC34
41. Tuccinardi T, Manetti F, Schenone S, Martinelli A, Botta M 2007 Construction and validation of a RET TK catalytic domain by homology modeling. J Chem Inf Model 47:644-655 (Pubitemid 46615965)
42. Celano M, Schenone S, Cosco D, Navarra M, Puxeddu E, Racanicchi L, Brullo C, Varano E, Alcaro S, Ferretti E, Botta G, Filetti S, Fresta M, Botta M, Russo D 2008 Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivo. Endocr Relat Cancer 15:499-510 (Pubitemid 351880838)